Topic: Moderna Vaccine

The development of RNA vaccines by companies like Moderna and CureVac offered a potential path to beating the traditional 18-month timeline for vaccine creation. Experts noted the difficulty of ensuring efficacy in elderly populations and the risks of side effects when deployed at a global scale. Bill Gates mentioned that governments would need to provide risk indemnification before a vaccine could be distributed to the entire world.

Early data from Moderna's vaccine trials showed that 80% of participants experienced systemic side effects like chills and fevers after the second dose. Experts noted that most leading vaccine candidates would require two doses, creating a massive logistical challenge for manufacturing and public compliance. Ensuring that elderly populations are well-represented in trials was identified as a priority for gathering accurate safety data.

Moderna abruptly halted its mRNA vaccine clinical trial for Respiratory Syncytial Virus (RSV) in children after data indicated the vaccine might worsen the disease. The FDA disclosed that vaccinated children in the trial experienced severe RSV at rates up to three times higher than the placebo group.

The FDA has authorized updated COVID-19 vaccines from Pfizer and Moderna targeting current variants. Additionally, the federal government plans to relaunch the covidtest.gov website in late September, allowing households to order four free rapid test kits despite the hosts' skepticism regarding the ongoing necessity of these measures.

Moderna announced positive trial results for a combined COVID-19 and flu vaccine, aiming for federal approval by 2025. Dr. Ashish Jha appeared on Chris Cuomo's show to promote the shot, dismissing concerns about mRNA by stating it is naturally present in every cell of the body. The hosts criticize the "native ad" style of the reporting and express skepticism about vaccine safety.

The U.S. government is reportedly nearing an agreement to fund Moderna's bird flu vaccine trials, causing the company's stock to rise. The hosts suggest the push for bird flu awareness is a precursor to implementing mail-in voting or new masking mandates. They discuss the transition from traditional egg-based vaccine manufacturing to mRNA "platforms" or "operating systems."

Former White House COVID response coordinator Dr. Ashish Jha appeared on the "Today Show" to promote the new COVID vaccine, suggesting it should be viewed as an "annual shot" similar to the flu vaccine. Jha stated it is safe to receive both the flu and COVID shots simultaneously. The segment is criticized as a marketing effort for pharmaceutical companies, noting the price hike from $20 to $120 per dose.

The hosts discuss the media coverage of the Moderna vaccine's Phase 3 clinical trials, noting that a similar trial by Pfizer received significantly less attention. They also play a clip of Fed Chairman Jerome Powell stating that while everyone wants a vaccine, they "can't plan on that" and must "plan for the worst."

BioNTech is launching clinical trials in the United Kingdom for personalized cancer vaccines using mRNA technology developed during the COVID-19 pandemic. The technology is described as "medicinal software" that can be rewritten to target specific proteins found in tumors. Proponents claim this platform will revolutionize the treatment of infectious diseases and chronic illnesses.

As the federal government stops purchasing COVID-19 vaccines in bulk, Pfizer and Moderna plan to raise prices to a range of $110 to $130 per dose on the open market. This represents a significant increase from the $26 per dose previously paid by the government. Jennifer Cates of the Kaiser Family Foundation notes that while insured individuals may not pay out-of-pocket, the costs will likely lead to higher insurance premiums.

Dr. Paul Offit, a member of the FDA Vaccine Advisory Committee, publicly warns that new COVID-19 boosters are being authorized based solely on mouse data rather than human clinical trials. He criticizes the FDA for not consulting its independent advisory committee, which he argues reduces transparency. The hosts suggest Offit is "covering his ass" as public sentiment shifts.

Speculation arises that COVID-19 vaccinations will become a permanent annual or even quarterly requirement, mirroring the business cycles of pharmaceutical companies. Germany's new vaccine passport system, which requires a booster every three months to maintain "up-to-date" status, is cited as a precursor to this global trend.

Global manufacturing capacity for the monkeypox vaccine is limited, with millions of doses previously discarded due to expiration. There is speculation that pharmaceutical companies like Pfizer or Moderna may develop mRNA-based solutions to address the shortage. The discussion explores whether the current health emergency will be used to further validate mRNA technology despite ongoing debates over COVID-19 vaccine performance.

Executive Producer Matt Hyde shared a detailed account of becoming severely ill after being forced to take a Pfizer booster on top of two Moderna doses for work travel. Hyde described symptoms including a constant high temperature, lethargy, and a subsequent heart attack, which his family doctor dismissed as unrelated to the vaccine. This story highlights the frustration of individuals facing medical gaslighting regarding potential adverse reactions.

Dr. Russell Blalock and other critics argue that the COVID-19 vaccines are linked to a "human tragedy of biblical proportions" and potential depopulation efforts. Concerns are raised regarding the lack of long-term safety studies, particularly for pregnant women and infants, as Moderna plans to test vaccines on babies as young as three months. The discussion cites rising instances of Sudden Adult Death Syndrome and myocarditis as evidence of vaccine harm.

Financial journalist Andrew Ross Sorkin questioned Scott Gottlieb regarding the necessity of a second booster for those over 50. Gottlieb predicted that the term "booster" will be replaced by "annual vaccine," mirroring the seasonal flu shot model. Both Pfizer and Moderna are developing Omicron-specific vaccines, with data expected to be released in May 2022.

The federal government is hiring trial attorneys to handle vaccine litigation under the National Childhood Vaccine Injury Act, signaling an expected increase in claims. Meanwhile, Moderna announced that its pediatric vaccine is roughly 38% to 44% effective in children under six. The hosts point out that these efficacy numbers are significantly lower than the 95% originally claimed for adults, yet the company is still pushing for emergency authorization by April.

Scientists in Israel reported that a fourth dose of the COVID-19 vaccine increases antibody levels but may not be sufficient to prevent breakthrough infections from the Omicron variant. Meanwhile, Moderna CEO Stéphane Bancel announced the company is developing a single annual booster shot that combines vaccines for both COVID-19 and the seasonal flu.

A viral video depicts a woman questioning a CVS pharmacist about the blank package inserts provided with the Moderna vaccine. The pharmacist admitted he could not provide full safety data or placebo studies and expressed a feeling of inadequacy regarding informed consent.

Dr. Michael Osterholm discusses the technical process of "tuning up" or "retooling" vaccines to target the Omicron variant. He suggests the FDA may treat these updates as "strain changes" similar to the annual influenza vaccine process, which could take four months to implement.